Molecular Docking studies of THC-HCA on Cancer Receptors
S Narendra Kumar1, Lingayya Hiremath2, Jyothsana R3, Rithika PravinIyer4, Ruchika PravinIyer5

1S Narendra Kumar, Assistant Professor, Department of Biotechnology, RV College of Engineering, Bangalore.
2Dr Lingayya Hiremath, Assistant Professor, Department of Biotechnology, RV College of Engineering, Bangalore.
3Jyothsana R, BE-Graduate Students, R V College of Engineering, Bengaluru RithikaPravin Iyer, BE-Graduate Students, R V College of Engineering, Bengaluru.
4RithikaPravin Iyer, BE-Graduate Students, R V College of Engineering, Bengaluru.
5RuchikaPravin Iyer, BE-Graduate Students, R V College of Engineering, Bengaluru.
Manuscript received on March 20, 2021. | Revised Manuscript received on March 26, 2021. | Manuscript published on April 10, 2021. | PP: 16-21 | Volume-1 Issue-1, Aprl 2021 | Retrieval Number:100.1/ijac.A2005101221
Open Access | Ethics and Policies | Indexing and Abstracting
© The Authors. Published by Lattice Science Publication (LSP). This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Abstract: Cancer is a group of diseases which involves abnormal cell growth that can spread to other parts of the body. There are certain characteristics that are required to produce a malignant tumour. They include: Avoidance of programmed cell death and uncontrolled cell division to name a few. The progression from normal cells to cells that can form a detectable mass to outright cancer involves multiple steps known as malignant progression. Cannabinoids are among the treatment available. Recent research has shown that cannabinoid coupled with hydroxy citric acid can be used in the treatment of melanoma. Hydroxy citric acid is a derivative of citric acid well known for its anti-obesity and anti-inflammatory property. The current project involves the coupling of tetrahydrocannabinol with hydroxy citric acid to develop a novel drug molecule for potential cancer treatment. Simulation tool like Argus lab is used to construct the 3D structure of the novel drug. Autodock was used to bind the drug with the receptors like TRPV1, CB1, CB2, 4QO1 and 2YGB.
Keywords: Hydroxycitric acid (HCA), cannabinoids, receptors, tetrahydrocannabinol (THC), ligand, docking, anti-inflammation, cancer therapeutics, p-53 proteins, Brest Cancer and Neuro cancer.